415 Capital

Supira Medical, Inc. is a medical technology company based in Campbell, California, focused on developing a percutaneous ventricular assist device (pVAD) designed for high-risk patients undergoing interventional procedures. This innovative device offers high-flow mechanical support during critical situations such as high-risk percutaneous coronary interventions (PCI) and cardiogenic shock. By assisting the heart's native pumping action, Supira Medical's solution enables patients with severe coronary artery disease or related comorbidities to safely undergo necessary interventions, thereby facilitating quicker recovery from heart-related issues. Founded in 2012 and originally known as Lumenblation Medical, Inc., the company rebranded in March 2016 to reflect its commitment to advancing cardiac care.

Endovascular Engineering is a preclinical stage company dedicated to advancing innovative mechanical thrombectomy solutions for peripheral medical conditions. The firm specializes in the development of clot removal technologies specifically designed to address venous thromboembolism, which encompasses critical health issues such as pulmonary embolism and deep vein thrombosis. By focusing on these areas, Endovascular Engineering aims to equip healthcare professionals with efficient and effective tools to enhance patient outcomes in the management of these vascular conditions.

R3 Vascular is a medical device company that specializes in developing and manufacturing bioresorbable vascular scaffolds for the treatment of peripheral arterial disease. The company utilizes proprietary polymer technologies to create scaffolds that effectively balance strength and flexibility. One of its key innovations is the magnitude BRS device, recognized as the thinnest bioresorbable scaffold tested in clinical settings, featuring a strut thickness of 98 microns across its usable diameter range. Additionally, R3 Vascular's products incorporate a sirolimus coating, which possesses anti-inflammatory properties, enhancing the efficacy of treatment for conditions affecting arteries below the knee.

Aktiia is a company focused on providing continuous and accurate blood pressure monitoring to address hypertension, a prevalent chronic condition affecting over 1.4 billion people globally. Founded on two decades of research, Aktiia has developed a unique tool that combines optical sensors with clinically validated software algorithms to measure blood pressure at the wrist. This innovative approach enables individuals to gain insights into their blood pressure patterns and understand the underlying causes of hypertension. By delivering personalized, continuous, and medical-grade blood pressure and heart rate data, Aktiia aims to enhance patient care and empower patients, researchers, and clinicians. The company's mission is to improve the accessibility, accuracy, and actionability of blood pressure management, ultimately contributing to better health outcomes and reducing the significant mortality associated with high blood pressure.

Supira Medical, Inc. is a medical technology company based in Campbell, California, focused on developing a percutaneous ventricular assist device (pVAD) designed for high-risk patients undergoing interventional procedures. This innovative device offers high-flow mechanical support during critical situations such as high-risk percutaneous coronary interventions (PCI) and cardiogenic shock. By assisting the heart's native pumping action, Supira Medical's solution enables patients with severe coronary artery disease or related comorbidities to safely undergo necessary interventions, thereby facilitating quicker recovery from heart-related issues. Founded in 2012 and originally known as Lumenblation Medical, Inc., the company rebranded in March 2016 to reflect its commitment to advancing cardiac care.

TRiCares is a medical device company focused on creating innovative solutions for tricuspid valve regurgitation. The company specializes in developing a catheter-based valve replacement system that facilitates minimally invasive treatments for patients suffering from tricuspid insufficiency. By emphasizing anatomical conformation and user-friendly design, TRiCares aims to provide effective and durable treatment options that improve patient outcomes. Through its advancements in medical technology, TRiCares addresses a critical need in cardiology, enhancing the quality of care for those affected by this condition.

Supira Medical, Inc. is a medical technology company based in Campbell, California, focused on developing a percutaneous ventricular assist device (pVAD) designed for high-risk patients undergoing interventional procedures. This innovative device offers high-flow mechanical support during critical situations such as high-risk percutaneous coronary interventions (PCI) and cardiogenic shock. By assisting the heart's native pumping action, Supira Medical's solution enables patients with severe coronary artery disease or related comorbidities to safely undergo necessary interventions, thereby facilitating quicker recovery from heart-related issues. Founded in 2012 and originally known as Lumenblation Medical, Inc., the company rebranded in March 2016 to reflect its commitment to advancing cardiac care.

Distalmotion, founded in Lausanne, Switzerland, is a medical device company dedicated to simplifying robotic surgery to enhance access to high-quality, minimally invasive care for patients in general surgery, gynecology, and urology. The company has developed a surgical robot named Dexter, which integrates the advantages of laparoscopy with those of robotics. Dexter offers an affordable solution by providing on-demand robotic surgery capabilities, combining cost-effectiveness with advanced surgical techniques.

Aktiia is a company focused on providing continuous and accurate blood pressure monitoring to address hypertension, a prevalent chronic condition affecting over 1.4 billion people globally. Founded on two decades of research, Aktiia has developed a unique tool that combines optical sensors with clinically validated software algorithms to measure blood pressure at the wrist. This innovative approach enables individuals to gain insights into their blood pressure patterns and understand the underlying causes of hypertension. By delivering personalized, continuous, and medical-grade blood pressure and heart rate data, Aktiia aims to enhance patient care and empower patients, researchers, and clinicians. The company's mission is to improve the accessibility, accuracy, and actionability of blood pressure management, ultimately contributing to better health outcomes and reducing the significant mortality associated with high blood pressure.

Cardiac Success is a medical technology company focused on developing innovative solutions to enhance cardiac function in patients suffering from heart failure and functional mitral regurgitation. The company's flagship product, the V-sling device, is a transcatheter ventricular repair device that draws upon a proven surgical technique known as papillary muscle approximation. This device aims to provide relief to patients experiencing heart failure with reduced ejection fraction, enabling them to improve their quality of life and manage critical heart conditions more effectively. Through its advancements, Cardiac Success strives to address significant challenges in cardiac care and contribute to better health outcomes for individuals with heart-related ailments.

CorFlow Therapeutics is a medtech startup focused on developing innovative technologies for the diagnosis and treatment of microvascular obstructions in patients experiencing heart attacks. The company has created a controlled flow infusion system that utilizes a proprietary concept to measure microvascular resistance, allowing interventional cardiologists to assess the severity of microvascular obstruction. By comparing these measurements with post-procedure contrast-enhanced magnetic resonance imaging, CorFlow's technology aims to improve the diagnosis and treatment of microvascular obstruction, potentially reducing both short- and long-term complications for severe heart attack patients. Through its advancements, CorFlow is committed to addressing significant unmet medical needs in cardiology.

Moray Medical is a company focused on developing innovative robotic delivery systems for structural heart therapies, specifically targeting edge-to-edge valve leaflet repair. The company aims to enhance the quality of life for millions affected by leaky heart valves by providing cardiologists with advanced tools for mitral valve clip therapies. Moray Medical's proprietary microfluidic robotics technology enables the precise and safe delivery of treatments, utilizing a compact, reusable fluid-drive system that features a digital interface for maneuvering flexible delivery catheters with ease, akin to using a computer cursor. This approach allows for cost-effective interventions, making life-saving heart valve therapies more accessible to a broader range of patients in need.

R3 Vascular is a medical device company that specializes in developing and manufacturing bioresorbable vascular scaffolds for the treatment of peripheral arterial disease. The company utilizes proprietary polymer technologies to create scaffolds that effectively balance strength and flexibility. One of its key innovations is the magnitude BRS device, recognized as the thinnest bioresorbable scaffold tested in clinical settings, featuring a strut thickness of 98 microns across its usable diameter range. Additionally, R3 Vascular's products incorporate a sirolimus coating, which possesses anti-inflammatory properties, enhancing the efficacy of treatment for conditions affecting arteries below the knee.

Supira Medical, Inc. is a medical technology company based in Campbell, California, focused on developing a percutaneous ventricular assist device (pVAD) designed for high-risk patients undergoing interventional procedures. This innovative device offers high-flow mechanical support during critical situations such as high-risk percutaneous coronary interventions (PCI) and cardiogenic shock. By assisting the heart's native pumping action, Supira Medical's solution enables patients with severe coronary artery disease or related comorbidities to safely undergo necessary interventions, thereby facilitating quicker recovery from heart-related issues. Founded in 2012 and originally known as Lumenblation Medical, Inc., the company rebranded in March 2016 to reflect its commitment to advancing cardiac care.